This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2024
  • /
  • 5
  • /
  • AC Immune SA and Takeda collaboration on ACI 24.06...

AC Immune SA and Takeda collaboration on ACI 24.060 for the treatment of Azheimer's disease

Read time: 1 mins
Published:14th May 2024

Takeda and AC Immune SA announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI 24.060 for the treatment of Alzheimer’s disease. ACI 24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression

By inducing plaque clearance and efficiently inhibiting potential to delay or slow Alzheimer’s disease progression. AC! 24.060 is being investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/II trial to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of the investigational immunotherapy in subjects with prodromal Alzheimer’s disease and in adults with Down's syndrome.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.